Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Filippini, Graziella; Clerico, Marinella; Beiki, Omid; Mattoscio, Miriam; Piazza, Federico; Giovane, Cinzia Del; Fredrikson, Sten; Tramacere, Irene; Scalfari, Antonio

doi:10.1002/14651858.cd012200

Cited by 3 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While early and efficient treatment reduces disease activity clinically and on MRI, a Cochrane review of adult multiple sclerosis studies showed no significant advantage of early disease‐modifying treatment (DMT) versus placebo on relapses and disability: DMTs resulted in small differences, based on low‐quality evidence. However, early DMT was associated with lower adherence to treatment in the long‐term . Currently the practice in most paediatric neurology clinics is to start DMT in patients aged 12 to 18 years at the first attack if the diagnosis of multiple sclerosis is certain by clinical and MRI criteria; if the criteria fit clinically isolated syndrome but not multiple sclerosis, the clinician should consider that about 40% to 50% of paediatric patients with clinically isolated syndrome receive a diagnosis of multiple sclerosis within 5 years.…”

Section: Multiphasic Diseasementioning

confidence: 99%

Treatment in childhood central nervous system demyelinating disorders

Konuşkan

Anlar

2019

Develop Med Child Neuro

View full text Add to dashboard Cite

The last two decades witnessed significant advances in the treatment of acquired demyelinating disorders: thirteen new agents have been approved for the treatment of multiple sclerosis in adults by the European Medicines Agency and US Food and Drug Administration in the last twenty years. Although the long‐term efficacy and safety profiles of some new drugs are still being assessed in paediatric MS, clinicians may have to use them in the management of paediatric onset MS resistant to first‐line medications, based on results obtained in adult‐onset disease. This review summarizes the current approach to treatment in children with demyelinating syndromes. What this paper adds Serological markers affect management in paediatric demyelinating diseases. Antibodies against aquaporin‐4 and myelin oligodendrocyte glycoprotein should be tested in children with acute demyelinating disease. New therapeutic agents currently in trial for pediatric disease should be used with close follow‐up.

show abstract

Section: Multiphasic Diseasementioning

confidence: 99%

Treatment in childhood central nervous system demyelinating disorders

Konuşkan

Anlar

2019

Develop Med Child Neuro

View full text Add to dashboard Cite

show abstract

“…Experimental autoimmune encephalomyelitis (EAE) is the classical animal model for MS's relevant research and exhibits similar characteristics of MS (Robinson et al 2014). At present, the drugs to treat MS are mainly hormones and immunosuppressants, with many side effects and are of high prices (Filippini et al 2017). Therefore, many scholars are committed to find active ingredients from natural compounds and explore new therapeutic drugs (Sanadgol et al 2017).…”

Section: Introductionmentioning

confidence: 99%

The mechanism of grape seed oligomeric procyanidins in the treatment of experimental autoimmune encephalomyelitis mice

Xue

Wang

Ding

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective This study aims to investigate the mechanism of grape seed oligomeric procyanidins (GPC) in the treatment of experimental autoimmune encephalomyelitis (EAE) mice, providing pharmacodynamic materials for drug development in the treatment of multiple sclerosis (MS). Methods The constituents which have nerve protective effect in GPC were collected through literature retrieval. We used PharmMapper and STITCH database to predict drug targets, GeneCards and OMIM database to predict MS-related genes. Targets of GPC treating MS were obtained from intersected targets between drug and disease. The GO functional enrichment and KEGG pathway enrichment analysis were performed by DAVID database. EAE mouse model was used to study the therapeutic mechanism of GPC. Results Forty-two targets were discovered to be related to the process of GPC treating MS. KEGG enriched a total of 32 pathways. The pharmacological experiment showed that GPC improved the clinical symptoms of EAE mice, inhibited the expression of indicators of oxidative stress and inflammatory response in CNS, and decreased the expression of P-Akt, P-ERK, and P-JNK. Conclusion The therapeutic effect of GPC in EAE mice is associated with the suppression of MAPK and PI3K-Akt signaling pathways, providing a theoretical basis for the application of GPC inMS.

show abstract

Clinicoradiological Factors for Predicting and Monitoring the Progression of Multiple Sclerosis

Yang

2024

J Mult Scler Neuroimmunol

View full text Add to dashboard Cite

As knowledge of pathophysiology and treatment options for multiple sclerosis has been expanding, decisions about when and which drugs we should start and switch appropriately have became important. It should be based upon individuals’ baseline clinical, environmental, demographical, and radiological biomarkers that correlate with long-term disability. In addition, a timely assessment of treatment response and adverse effect should be followed after the initial treatment. Several prognostication tools were developed and large longitudinal studies validated them. They consisted of composition of demographical factors, clinical relapse rate, relapse severity, involvement of specific functional system, magnetic resonance imaging activity and characteristic findings (gadolinium enhancement, brain atrophy, and paramagnetic rim lesion, etc.).

show abstract

Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Abstract: Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.

Cited by 3 publications

References 58 publications

Treatment in childhood central nervous system demyelinating disorders

Treatment in childhood central nervous system demyelinating disorders

The mechanism of grape seed oligomeric procyanidins in the treatment of experimental autoimmune encephalomyelitis mice

Clinicoradiological Factors for Predicting and Monitoring the Progression of Multiple Sclerosis

Contact Info

Product

Resources

About